Ror2-mediated alternative Wnt signaling regulates cell fate and adhesion during mammary tumor progression

Oncogene

Volumn 36, Issue 43, 2017, Pages 5958-5968

  Roarty, K ^a   Pfefferle, A D ^b   Creighton, C J ^a   Perou, C M ^b   Rosen, J M ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; BETA1 INTEGRIN; CD24 ANTIGEN; CLAUDIN; DESMOGLEIN; DISHEVELLED 2; F ACTIN; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; LENTIVIRUS VECTOR; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 5; MEMBRANE RECEPTOR; ONCOPROTEIN; PROTEIN C JUN; PROTEIN TYROSINE KINASE; RECEPTOR TYROSINE KINASE ROR2; REGULATOR PROTEIN; RHO ASSOCIATED COILED COIL CONTAINING PROTEIN KINASE 1; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; RHO KINASE; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; SHORT HAIRPIN RNA; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG; WNT PROTEIN; WNT10A PROTEIN; WNT10B PROTEIN; WNT11 PROTEIN; WNT5A PROTEIN; WNT5B PROTEIN; WNT6 PROTEIN; WNT7B PROTEIN; DISHEVELLED PROTEIN; DVL2 PROTEIN, MOUSE; PROTEIN P53; RECEPTOR TYROSINE KINASE LIKE ORPHAN RECEPTOR; RHOA PROTEIN, MOUSE; ROCK1 PROTEIN, MOUSE; ROR2 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BASAL LIKE BREAST CANCER; BREAST CARCINOGENESIS; CANCER GROWTH; CELL ADHESION; CELL FATE; CELL FUNCTION; CELL HETEROGENEITY; CELL MIGRATION; CELL PLASTICITY; CELL POPULATION; CONTROLLED STUDY; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE SILENCING; IN VIVO STUDY; MOUSE; NONHUMAN; NUCLEAR REPROGRAMMING; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN FUNCTION; SPATIOTEMPORAL ANALYSIS; TUMOR DIFFERENTIATION; UPREGULATION; WNT SIGNALING; ANIMAL; BREAST TUMOR; EXPERIMENTAL MAMMARY NEOPLASM; GENETICS; HUMAN; PATHOLOGY;

ANIMALS; BETA CATENIN; BREAST NEOPLASMS; CELL ADHESION; DISHEVELLED PROTEINS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MAMMARY NEOPLASMS, ANIMAL; MICE; RECEPTOR TYROSINE KINASE-LIKE ORPHAN RECEPTORS; RHO GTP-BINDING PROTEINS; RHO-ASSOCIATED KINASES; TUMOR SUPPRESSOR PROTEIN P53; WNT SIGNALING PATHWAY;

EID: 85032491354     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2017.206     Document Type: Article

References (75)

1. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA et al. Molecular portraits of human breast tumours. Nature 2000; 406: 747-752.
2. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001; 98: 10869-10874.
3. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003; 100: 8418-8423.
4. Prat A, Perou CM. Deconstructing the molecular portraits of breast cancer. Mol Oncol 2011; 5: 5-23.
5. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 2011; 121: 2750-2767.
6. Prat A, Perou CM. Mammary development meets cancer genomics. Nat Med 2009; 15: 842-844.
7. Prat A, Parker JS, Karginova O, Fan C, Livasy C, Herschkowitz JI et al. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res 2010; 12: R68.
8. Russnes HG, Navin N, Hicks J, Borresen-Dale AL. Insight into the heterogeneity of breast cancer through next-generation sequencing. J Clin Invest 2011; 121: 3810-3818.
9. Angers S, Moon RT. Proximal events in Wnt signal transduction. Nat Rev Mol Cell Biol 2009; 10: 468-477.
10. Clevers H, Loh KM, Nusse R. Stem cell signaling. An integral program for tissue renewal and regeneration: Wnt signaling and stem cell control. Science 2014; 346: 1248012.
11. van Amerongen R. Alternative Wnt pathways and receptors. Cold Spring Harb Perspect Biol 2012; 4: a007914.
12. van Amerongen R, Nusse R. Towards an integrated view of Wnt signaling in development. Development 2009; 136: 3205-3214.
13. Beermann A, Pruhs R, Lutz R, Schroder R. A context-dependent combination of Wnt receptors controls axis elongation and leg development in a short germ insect. Development 2011; 138: 2793-2805.
14. Mikels AJ, Nusse R. Purified Wnt5a protein activates or inhibits beta-catenin-TCF signaling depending on receptor context. PLoS Biol 2006; 4: e115.
15. Ho HY, Susman MW, Bikoff JB, Ryu YK, Jonas AM, Hu L et al. Wnt5a-Ror-Dishevelled signaling constitutes a core developmental pathway that controls tissue morphogenesis. Proc Natl Acad Sci USA 2012; 109: 4044-4051.
16. Yamaguchi TP, Bradley A, McMahon AP, Jones S. A Wnt5a pathway underlies outgrowth of multiple structures in the vertebrate embryo. Development 1999; 126: 1211-1223.
17. Takeuchi S, Takeda K, Oishi I, Nomi M, Ikeya M, Itoh K et al. Mouse Ror2 receptor tyrosine kinase is required for the heart development and limb formation. Genes Cells 2000; 5: 71-78.
18. DeChiara TM, Kimble RB, Poueymirou WT, Rojas J, Masiakowski P, Valenzuela DM et al. Ror2, encoding a receptor-like tyrosine kinase, is required for cartilage and growth plate development. Nat Genet 2000; 24: 271-274.
19. Polakis P. Wnt signaling in cancer. Cold Spring Harb Perspect Biol 2012; 4: a008052.
20. Chakrabarti R, Wei Y, Hwang J, Hang X, Andres Blanco M, Choudhury A et al. DeltaNp63 promotes stem cell activity in mammary gland development and basal-like breast cancer by enhancing Fzd7 expression and Wnt signalling. Nat Cell Biol 2014; 16: 1004-1015, 1-13.
21. Geyer FC, Lacroix-Triki M, Savage K, Arnedos M, Lambros MB, MacKay A et al. Beta-Catenin pathway activation in breast cancer is associated with triple-negative phenotype but not with CTNNB1 mutation. Mod Pathol 2011; 24: 209-231.
22. Khramtsov AI, Khramtsova GF, Tretiakova M, Huo D, Olopade OI, Goss KH. Wnt/ beta-catenin pathway activation is enriched in basal-like breast cancers and predicts poor outcome. Am J Pathol 2010; 176: 2911-2920.
23. Puvirajesinghe TM, Bertucci F, Jain A, Scerbo P, Belotti E, Audebert S et al. Identification of p62/SQSTM1 as a component of non-canonical Wnt VANGL2-JNK signalling in breast cancer. Nat Commun 2016; 7: 10318.
24. Gujral TS, Chan M, Peshkin L, Sorger PK, Kirschner MW, MacBeath G. A noncanonical Frizzled2 pathway regulates epithelial-mesenchymal transition and metastasis. Cell 2014; 159: 844-856.
25. Zhang S, Chen L, Cui B, Chuang HY, Yu J, Wang-Rodriguez J et al. ROR1 is expressed in human breast cancer and associated with enhanced tumorcell growth. PLoS One 2012; 7: e31127.
26. Henry C, Quadir A, Hawkins NJ, Jary E, Llamosas E, Kumar D et al. Expression of the novel Wnt receptor ROR2 is increased in breast cancer and may regulate both beta-catenin dependent and independent Wnt signalling. J Cancer Res Clin Oncol 2015; 141: 243-254.
27. Jonsson M, Dejmek J, Bendahl PO, Andersson T. Loss of Wnt-5a protein is associated with early relapse in invasive ductal breast carcinomas. Cancer Res 2002; 62: 409-416.
28. Lejeune S, Huguet EL, Hamby A, Poulsom R, Harris AL. Wnt5a cloning, expression, and up-regulation in human primary breast cancers. Clin Cancer Res 1995; 1: 215-222.
29. Herschkowitz JI, Zhao W, Zhang M, Usary J, Murrow G, Edwards D et al. Comparative oncogenomics identifies breast tumors enriched in functional tumorinitiating cells. Proc Natl Acad Sci USA 2012; 109: 2778-2783.
30. Jerry DJ, Kittrell FS, Kuperwasser C, Laucirica R, Dickinson ES, Bonilla PJ et al. A mammary-specific model demonstrates the role of the p53 tumor suppressor gene in tumor development. Oncogene 2000; 19: 1052-1058.
31. Medina D, Kittrell FS, Shepard A, Stephens LC, Jiang C, Lu J et al. Biological and genetic properties of the p53 null preneoplastic mammary epithelium. FASEB J 2002; 16: 881-883.
32. Fuerer C, Nusse R. Lentiviral vectors to probe and manipulate the Wnt signaling pathway. PLoS ONE 2010; 5: e9370.
33. Zhang M, Atkinson RL, Rosen JM. Selective targeting of radiation-resistant tumorinitiating cells. Proc Natl Acad Sci USA 2010; 107: 3522-3527.
34. Roarty K, Shore AN, Creighton CJ, Rosen JM. Ror2 regulates branching, differentiation, and actin-cytoskeletal dynamics within the mammary epithelium. J Cell Biol 2015; 208: 351-366.
35. Oishi I, Takeuchi S, Hashimoto R, Nagabukuro A, Ueda T, Liu ZJ et al. Spatiotemporally regulated expression of receptor tyrosine kinases, mRor1, mRor2, during mouse development: implications in development and function of the nervous system. Genes Cells 1999; 4: 41-56.
36. Green JL, La J, Yum KW, Desai P, Rodewald LW, Zhang X et al. Paracrine Wnt signaling both promotes and inhibits human breast tumor growth. Proc Natl Acad Sci USA 2013; 110: 6991-6996.
37. Dembowy J, Adissu HA, Liu JC, Zacksenhaus E, Woodgett JR. Effect of glycogen synthase kinase-3 inactivation on mouse mammary gland development and oncogenesis. Oncogene 2015; 34: 3514-3526.
38. Miyoshi K, Rosner A, Nozawa M, Byrd C, Morgan F, Landesman-Bollag E et al. Activation of different Wnt/beta-catenin signaling components in mammary epithelium induces transdifferentiation and the formation of pilar tumors. Oncogene 2002; 21: 5548-5556.
39. Rosner A, Miyoshi K, Landesman-Bollag E, Xu X, Seldin DC, Moser AR et al. Pathway pathology: histological differences between ErbB/Ras and Wnt pathway transgenic mammary tumors. Am J Pathol 2002; 161: 1087-1097.
40. Prat A, Karginova O, Parker JS, Fan C, He X, Bixby L et al. Characterization of cell lines derived from breast cancers and normal mammary tissues for the study of the intrinsic molecular subtypes. Breast Cancer Res Treat 2013; 142: 237-255.
41. Schlessinger K, Hall A, Tolwinski N. Wnt signaling pathways meet Rho GTPases. Genes Dev 2009; 23: 265-277.
42. Martelotto LG, Ng CK, Piscuoglio S, Weigelt B, Reis-Filho JS. Breast cancer intratumor heterogeneity. Breast Cancer Res 2013; 16: 210.
43. Ng CK, Pemberton HN, Reis-Filho JS. Breast cancer intratumor genetic heterogeneity: causes and implications. Expert Rev Anticancer Ther 2012; 12: 1021-1032.
44. Brechbuhl HM, Ghosh M, Smith MK, Smith RW, Li B, Hicks DA et al. Beta-catenin dosage is a critical determinant of tracheal basal cell fate determination. Am J Pathol 2011; 179: 367-379.
45. Luis TC, Naber BA, Roozen PP, Brugman MH, de Haas EF, Ghazvini M et al. Canonical wnt signaling regulates hematopoiesis in a dosage-dependent fashion. Cell Stem Cell 2011; 9: 345-356.
46. Aulehla A, Wiegraebe W, Baubet V, Wahl MB, Deng C, Taketo M et al. A betacatenin gradient links the clock and wavefront systems in mouse embryo segmentation. Nat Cell Biol 2008; 10: 186-193.
47. Gao B, Song H, Bishop K, Elliot G, Garrett L, English MA et al. Wnt signaling gradients establish planar cell polarity by inducing Vangl2 phosphorylation through Ror2. Dev Cell 2011; 20: 163-176.
48. Wang J, Sinha T, Wynshaw-Boris A. Wnt signaling in mammalian development: lessons from mouse genetics. Cold Spring Harb Perspect Biol 2012; 4: a007963.
49. Grumolato L, Liu G, Mong P, Mudbhary R, Biswas R, Arroyave R et al. Canonical and noncanonical Wnts use a common mechanism to activate completely unrelated coreceptors. Genes Dev 2010; 24: 2517-2530.
50. Borcherding N, Kusner D, Kolb R, Xie Q, Li W, Yuan F et al. Paracrine WNT5A signaling inhibits expansion of tumor-initiating cells. Cancer Res 2015; 75: 1972-1982.
51. Dass RA, Sarshad AA, Carson BB, Feenstra JM, Kaur A, Obrdlik A et al. Wnt5a signals through DVL1 to repress ribosomal DNA transcription by RNA polymerase I. PLoS Genet 2016; 12: e1006217.
52. Jiang W, Crossman DK, Mitchell EH, Sohn P, Crowley MR, Serra R. WNT5A inhibits metastasis and alters splicing of Cd44 in breast cancer cells. PLoS ONE 2013; 8: e58329.
53. Roarty K, Baxley SE, Crowley MR, Frost AR, Serra R. Loss of TGF-beta or Wnt5a results in an increase in Wnt/beta-catenin activity and redirects mammary tumour phenotype. Breast Cancer Res 2009; 11: R19.
54. Shi J, Wang Y, Zeng L, Wu Y, Deng J, Zhang Q et al. Disrupting the interaction of BRD4 with diacetylated Twist suppresses tumorigenesis in basal-like breast cancer. Cancer Cell 2014; 25: 210-225.
55. Fehon RG, McClatchey AI, Bretscher A. Organizing the cell cortex: the role of ERM proteins. Nat Rev Mol Cell Biol 2010; 11: 276-287.
56. Neisch AL, Fehon RG. Ezrin, Radixin and Moesin: key regulators of membranecortex interactions and signaling. Curr Opin Cell Biol 2011; 23: 377-382.
57. Arpin M, Chirivino D, Naba A, Zwaenepoel I. Emerging role for ERM proteins in cell adhesion and migration. Cell Adh Migr 2011; 5: 199-206.
58. Clucas J, Valderrama F. ERM proteins in cancer progression. J Cell Sci 2014; 127(Pt 2): 267-275.
59. Ren L, Hong SH, Cassavaugh J, Osborne T, Chou AJ, Kim SY et al. The actincytoskeleton linker protein ezrin is regulated during osteosarcoma metastasis by PKC. Oncogene 2009; 28: 792-802.
60. Lawson CD, Fan C, Mitin N, Baker NM, George SD, Graham DM et al. Rho GTPase transcriptome analysis reveals oncogenic roles for Rho GTPase-activating proteins in basal-like breast cancers. Cancer Res 2016; 76: 3826-3837.
61. Lim E, Vaillant F, Wu D, Forrest NC, Pal B, Hart AH et al. Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nat Med 2009; 15: 907-913.
62. Cleary AS, Leonard TL, Gestl SA, Gunther EJ. Tumour cell heterogeneity maintained by cooperating subclones in Wnt-driven mammary cancers. Nature 2014; 508: 113-117.
63. Zhang M, Tsimelzon A, Chang CH, Fan C, Wolff A, Perou CM et al. Intratumoral heterogeneity in a Trp53-null mouse model of human breast cancer. Cancer Discov 2015; 5: 520-533.
64. Creighton CJ, Li X, Landis M, Dixon JM, Neumeister VM, Sjolund A et al. Residual breast cancers after conventional therapy display mesenchymal as well as tumorinitiating features. Proc Natl Acad Sci USA 2009; 106: 13820-13825.
65. Gluck S, Ross JS, Royce M, McKenna Jr EF, Perou CM, Avisar E et al. TP53 genomics predict higher clinical and pathologic tumor response in operable early-stage breast cancer treated with docetaxel-capecitabine +/-trastuzumab. Breast Cancer Res Treat 2012; 132: 781-791.
66. Liedtke C, Mazouni C, Hess KR, Andre F, Tordai A, Mejia JA et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 2008; 26: 1275-1281.
67. Waclaw B, Bozic I, Pittman ME, Hruban RH, Vogelstein B, Nowak MA. A spatial model predicts that dispersal and cell turnover limit intratumour heterogeneity. Nature 2015; 525: 261-264.
68. Weber K, Bartsch U, Stocking C, Fehse B. A multicolor panel of novel lentiviral 'gene ontology' (LeGO) vectors for functional gene analysis. Mol Ther 2008; 16: 698-706.
69. Pfefferle AD, Herschkowitz JI, Usary J, Harrell JC, Spike BT, Adams JR et al. Transcriptomic classification of genetically engineered mouse models of breast cancer identifies human subtype counterparts. Genome Biol 2013; 14: R125.
70. Herschkowitz JI, Simin K, Weigman VJ, Mikaelian I, Usary J, Hu Z et al. Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol 2007; 8: R76.
71. Creighton CJ, Casa A, Lazard Z, Huang S, Tsimelzon A, Hilsenbeck SG et al. Insulinlike growth factor-I activates gene transcription programs strongly associated with poor breast cancer prognosis. J Clin Oncol 2008; 26: 4078-4085.
72. Huang S, Li Y, Chen Y, Podsypanina K, Chamorro M, Olshen AB et al. Changes in gene expression during the development of mammary tumors in MMTV-Wnt-1 transgenic mice. Genome Biol 2005; 6: R84.
73. Creighton CJ, Hernandez-Herrera A, Jacobsen A, Levine DA, Mankoo P, Schultz N et al. Integrated analyses of microRNAs demonstrate their widespread influence on gene expression in high-grade serous ovarian carcinoma. PLoS One 2012; 7: e34546.
74. Creighton CJ, Nagaraja AK, Hanash SM, Matzuk MM, Gunaratne PH. A bioinformatics tool for linking gene expression profiling results with public databases of microRNA target predictions. RNA 2008; 14: 2290-2296.
75. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA 2001; 98: 5116-5121.